Product nameAnti-VEGF Receptor 2 antibody [EPRER16Y]
See all VEGF Receptor 2 primary antibodies
DescriptionRabbit monoclonal [EPRER16Y] to VEGF Receptor 2
SpecificityIt is predicted that ab134191 does not cross react with other members of the VEGF receptor family.
Tested applicationsSuitable for: WB, IPmore details
Unsuitable for: Flow Cyt,ICC or IHC-P
Species reactivityReacts with: Human
Recombinant fragment within Human VEGF Receptor 2 aa 1-800. The exact sequence is proprietary.
- Human placenta lysate
A trial size is available to purchase for this antibody.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.
This product is a recombinant rabbit monoclonal antibody.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C.
Storage bufferpH: 7.40
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab134191 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Detects a band of approximately 210, 230 kDa (predicted molecular weight: 151 kDa).|
FunctionReceptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
Involvement in diseaseDefects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma.
Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain.
modificationsPhosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.
- Information by UniProt
- CD309 antibody
- CD309 antigen antibody
- EC 184.108.40.206 antibody
Anti-VEGF Receptor 2 antibody [EPRER16Y] (ab134191) at 1/500 dilution + Human placenta lysate at 10 µg
HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 151 kDa
Observed band size: 210,230 kDa why is the actual band size different from the predicted?
This product has been referenced in:
- Xu JG et al. Inhibition of TGF-ß Signaling in SHED Enhances Endothelial Differentiation. J Dent Res 97:218-225 (2018). Read more (PubMed: 28972822) »
- Li Y et al. Integrin-Linked Kinase Senses Hypoxia During Scar Angiogenesis. Int J Low Extrem Wounds N/A:N/A (2016). Read more (PubMed: 27230895) »